Company Description
ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products.
The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services.
It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.
The company also commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient NIAGEN; NIAGEN as an active ingredient in its consumer products under the TRU NIAGEN name; and Immulina, a spirulina extract with predominant active compounds of Braun-type lipoproteins for supporting human immune function.
In addition, it offers phytochemical reference standards, and other research and development services.
The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, ShopHQ, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States.
ChromaDex Corporation was founded in 1999 and is headquartered in Los Angeles, California.
| Country | United States |
| Founded | 1999 |
| Industry | Packaged Foods |
| Sector | Consumer Staples |
| Employees | 106 |
| CEO | Robert Fried |
Contact Details
Address: 10900 Wilshire Blvd, Suite 600 Los Angeles, California 90024 United States | |
| Phone | 310 388 6706 |
| Website | chromadex.com |
Stock Details
| Ticker Symbol | CDXC |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001386570 |
| CUSIP Number | 171077407 |
| ISIN Number | US1710774076 |
| Employer ID | 26-2940963 |
| SIC Code | 2833 |
Key Executives
| Name | Position |
|---|---|
| Robert N. Fried | Chief Executive Officer and Director |
| Frank Louis Jaksch Jr. | Co-Founder and Chairman |
| Ozan Pamir C.F.A. | Chief Financial Officer and Principal Accounting Officer |
| Dr. Andrew Shao Ph.D. | Senior Vice President of Global Regulatory and Scientific Affairs |
| Carlos Lopez | Senior Vice President and General Counsel |
| Alex Worsham | Vice President of Global Marketing and Communications |
| Chu Yan | Managing Director of Asia Pacific |
| Kendall Knysch | Head of Media Relations and Partnerships |
| James Lee | Controller |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 31, 2024 | 8-K | Current Report |
| Oct 31, 2024 | 10-Q | Quarterly Report |
| Oct 11, 2024 | 8-K | Current Report |
| Sep 20, 2024 | 8-K | Current Report |
| Aug 23, 2024 | 144 | Filing |
| Aug 21, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Aug 21, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Aug 7, 2024 | 8-K | Current Report |
| Aug 7, 2024 | 10-Q | Quarterly Report |
| Jul 16, 2024 | 8-K | Current Report |